Authors
Latest:
Complicated vs Complex Challenges in PharmaMost challenges boil down to two simple categories: "complicated" and "complex". Knowing how to categorize each problem is key to solving it, writes Steve Figman.
Latest:
The Reluctant Customer: Using Personas to Improve ComplianceConsumers of life sciences products are reluctant customers, and this reluctance can turn into non-compliance. Organizations and providers need to understand patients at a human level, and what will motivate them to stay with a treatment plan, writes John Pagliuca.
Latest:
Could Valeant Pharmaceuticals Have Gifted Teva its "Biggest Commercial Hope"?Intellectual property analysis of one recently approved drug shows how Valiant might have missed out on at least one vital acquisition opportunity. Duncan Clark reports.
Latest:
Ukraine: Protecting Investments through Entry Agreements Between Pharma and GovernmentLana Sinichkina, Kateryna Oliinyk and Yevgeniya Ocheretko discuss how the recent settlement between Gilead and Ukraine's Ministry of Health could promote earlier market access in the country.
Latest:
Charting an Effective Big Data StrategyBig data has proven to be a valuable business asset, but using it to gain competitive advantage requires the right combination of strategy, technology and execution, write Mahmood Majeed, Vickye Jain, and Sandeep Varma.
Latest:
News Spotlight: PharmaPharm Exec’s 13th Annual Press Audit audit reveals a tonal undercurrent in sync with an industry unable to escape the glare of scrutiny.
Latest:
Opioid Litigation: Evading the Widening CrosshairsThe role of insurance and risk management in protecting middle-market distributors from the growing opioid multi-district litigation (MDL).
Latest:
Can AI Improve Sales Productivity in Pharma?With the physician-access climate as daunting as ever for sales reps, four best practices in implementing artificial intelligence-based technology to help achieve engagement wins are explored.
Latest:
Building a Digital Health InfrastructureOutlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.
Latest:
Challenging the Current Compliance ParadigmPharma needs a reeducation on what it means to be compliant.
Latest:
Leveraging Health IT to Improve Drug DevelopmentThe FDA's Mary Ann Slack outlines how the Agency is working to adopt electronic practices by initiating efforts to simplify the submission process for new drug and generic drug applications.
Latest:
Targeting the Affluent: Differential Access to Targeted Therapies in ChinaDisparities in income levels in China continue to drive far-reaching differences in how poorer and richer cancer patients are treated, with recent data suggesting that the differences in access to treatment lead to different outcomes for poorer patients. Peter De Richter reports.
Latest:
Branded Generics in the Emerging MarketsBranded generics in select emerging markets can offer above-market returns, writes Renaud Savary.
Latest:
The Fundamental Pillars of Good ForecastingMaiko Midena discusses the key fundamentals to success when it comes to forecasting with large multinational pharmaceutical organizations.
Latest:
Leveraging Health IT to Improve Drug DevelopmentThe FDA's Mary Ann Slack outlines how the Agency is working to adopt electronic practices by initiating efforts to simplify the submission process for new drug and generic drug applications.
Latest:
Global Harmonization of Customer DataCherry Cabading and Mona Rakibe outline how the use of modern data management techniques can help companies see improvements in sales effectiveness, data steward productivity and overall data quality.
Latest:
Syncing Social Media With Value-Care ModelOutlining the new communication priorities necessary to excel in the emerging outcomes-based healthcare landscape.
Latest:
Why Pharma Needs to Catch Up On DigitalA recent IT leadership survey found that many more pharma companies are reporting their digital strategies are ineffective compared to other industries. Heath Jackson looks at why this is – and what they need to do about it.
Latest:
Avoiding a CIA: Analytics and the Search for Dangerous DataInternal oversight and the tools to remain compliant are critical to companies seeking to avoid corporate integrity agreements (CIAs) or efficiently fulfill existing agreements. In either case, CIAs can be a business advantage, writes Gabriela P. Baron.
Latest:
mAb Biosimilars: The Future of Cancer Treatment?Time will determine the shape of biosimilar usage in oncology, but they will play a significant role in the battle against cancer in the future, writes Alessandra Franceschetti.
Latest:
Beyond the Science: Commercial Implications From ASCO 2017Four strategic takeaways from this year's that are important for pharma oncology leaders.
Latest:
The Future of Real-World StudiesPharma companies today must increasingly provide evidence on real-world outcomes to differentiate and justify their products. But what is the true potential of real-world evidence studies and what are the right questions to ask in determining product performance in the marketplace?
Latest:
How Emerging Biopharmas Can Obtain VC FundingKen Shimokawa, Founder and General Partner of G4S Capital, shares insights into what venture capitalists look for when evaluating emerging biopharmaceutical opportunities.
Latest:
Aligning Early Advice with Long-Term PlanningThe five ways pharma developers can get the most out of early engagement with payers and regulators when plotting their clinical and commercial evidence plans.
Latest:
Time to Disrupt SOPsPharma companies still keep thousands of manufacturing procedures as text documents, an inefficient method can lead to defective batches, recalls and warning letters. Why not use video for training where applicable, asks Boaz Sigelman.
Latest:
Packaging for Patient EngagementFunso Olufade discusses how solutions such as the new Adherence Package can help increase pharma–patient engagement.
